UPCI Investigation Drug Service (IDS) is directed by Rowena Schwartz, Pharm.D., BCOP and managed by Carol L. Matthews, R.Ph. The UPCI IDS oversees all pharmacy procedures and processes for IDS and clinical sites where UPCI sponsored studies are implemented. The service is responsible for coordinating and managing the investigational drug inventory, storage, distribution, and record keeping for UPCI clinical research studies. The IDS has moved into the Hillman Cancer Center and three additional UPMC cancer centers have opened in the Western Pennsylvania region increasing off site locations requiring additional efforts and time for implementation and ongoing coordination and monitoring of studies. The IDS will be working closely with the UPCI efforts in the recently funded NCI grant for overcoming barriers to participation in early clinical trials at community-based locations. The IDS will continue to facilitate the conduct of early phase clinical trials throughout the network sites by developing strategies for drug preparation and delivery in sites that are not currently involved in clinical trials. All protocols are reviewed by Ms. Matthews early in the developmental phase to identify any IDS related issues including the pharmaceutical and clinical pharmacy requirements. This review includes an assessment of drug handling issues, implementation requirements, development of procedures for drug preparation at each treatment site and study related drug costs on the impact of protocol development and implementation. The IDS is also responsible for the education of pharmacists throughout the network who will be handling the drugs or agents for each protocol. The IDS is responsible for working with new clinical sites to develop appropriate processes for drug handling and preparation. The IDS is responsible for drug management, investigational drug supply including development of protocol specific pharmacy procedures for drug management that can be adapted to each participating clinical site, development and/or adaptation of protocol specific guidelines for written medication or medications used in the clinical studies, maintaining all investigational medications in secured areas of clinical sites, maintaining drug accountability records for invesfigational medications, coordination of medication distribution of the clinical sites involved in clinical studies, and routine quality assurance of drug handling. Quality assurance includes monitoring of drug accountability records, a coding system, and a form to calculate dose for specific protocols. The IDS will provide important infrastructure support for the coordination of studies within the UPMC cancer's network and will work with each clinical site to develop the appropriate implementation plan on a protocol by protocol basis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-18
Application #
7111835
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2005-08-01
Budget End
2006-07-31
Support Year
18
Fiscal Year
2005
Total Cost
$74,897
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Zahorchak, Alan F; Macedo, Camila; Hamm, David E et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol 323:9-18
Rogers, Meredith C; Lamens, Kristina D; Shafagati, Nazly et al. (2018) CD4+ Regulatory T Cells Exert Differential Functions during Early and Late Stages of the Immune Response to Respiratory Viruses. J Immunol 201:1253-1266
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15
Jing, Y; Nguyen, M M; Wang, D et al. (2018) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene 37:638-650
Singh, Krishna B; Ji, Xinhua; Singh, Shivendra V (2018) Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Mol Cancer Ther 17:2079-2090
Gao, Ying; Tan, Jun; Jin, Jingyi et al. (2018) SIRT6 facilitates directional telomere movement upon oxidative damage. Sci Rep 8:5407
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Santos, Patricia M; Butterfield, Lisa H (2018) Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology 155:1684-1686
Liu, Zuqiang; Ge, Yan; Wang, Haiyan et al. (2018) Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2. Nat Commun 9:4682

Showing the most recent 10 out of 1187 publications